Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2.
Saved in:
| Title: | Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2. |
|---|---|
| Authors: | Casás-Selves M; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.; Present address: Drug Discovery Program, Ontario Institute for Cancer Research, 661 University Avenue, Suite 510, Toronto, ON, M5G 0A3, Canada., Zhang AX; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Dowling JE; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Hallén S; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Discovery Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden., Kawatkar A; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Pace NJ; Department of Chemistry, Boston College, Chestnut Hill, MA, 02467, USA., Denz CR; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Pontz T; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Garahdaghi F; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.; Present address: Synageva BioPharma Corp., 33 Hayden Avenue, Lexington, MA, 02421, USA., Cao Q; Discovery Sciences-Computational Chemistry, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.; Present address: Ra Pharmaceuticals, Inc., 87 Cambridge Park Drive, Cambridge, MA, 02140, USA., Sabirsh A; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Discovery Unit, AstraZeneca, Pepparedsleden 1, Mölndal, 431 83, Sweden., Thakur K; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., O'Connell N; Discovery Sciences-Structure and Biophysics, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.; Present address: Nurix, Inc., 1700 Owens Street, Suite 290, San Francisco, CA, 94158, USA., Hu J; Discovery Sciences-Structure and Biophysics, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.; Present address: Shire, 300 Shire Way, Lexington, MA, 02421, USA., Cornella-Taracido I; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.; Present address: Discovery Chemistry, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA, 02115, USA., Weerapana E; Department of Chemistry, Boston College, Chestnut Hill, MA, 02467, USA., Zinda M; Oncology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA., Goodnow RA Jr; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA.; Present address: Pharmaron, 303 Wyman Street, Room 322, Waltham, MA, 02451, USA., Castaldi MP; Discovery Sciences-Chemical Biology, Innovative Medicines and Early Discovery Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA, 02451, USA. |
| Source: | ChemMedChem [ChemMedChem] 2017 Jun 21; Vol. 12 (12), pp. 917-924. Date of Electronic Publication: 2017 Apr 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-VCH Country of Publication: Germany NLM ID: 101259013 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1860-7187 (Electronic) Linking ISSN: 18607179 NLM ISO Abbreviation: ChemMedChem Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
